Donate

Prof. Sue Burchill

MRG Lead – Children’s Cancer Translational Research
Professor of childhood and adolescent cancer research, University of Leeds
Find out more
Sue_Burchill

Bio

Sue joined the University of Leeds in 1992 and is the scientific director of the Children’s Cancer Research Group at St James’s University Hospital. Sue’s primary research interest is metastatic drug-resistant disease that poses the most difficult challenge for the management and successful treatment of many children and young people with cancer. Her focus is the development of strategies to detect and eradicate the cells responsible for progression and relapse in neuroblastoma and Ewing sarcoma. Sue’s leadership in multi-disciplinary collaborative groups includes shaping international strategies for the evaluation of circulating biomarkers in these cancers.

Projects led by Prof. Sue Burchill

Children’s Cancer Translational Research

Driving evidence-based improvements in outcomes for children and young people living with and beyond cancer.
Find out more

Publications by Prof. Sue Burchill

Date published: January 8, 2024
Authors: Lucas Moreno, Rebekah Weston, Cormac Owens, Dominique Valteau-Couanet, Marion Gambart, Victoria Castel, C Michel Zwaan, Karsten Nysom, Nicolas Gerber, Aurora Castellano, Genevieve Laureys, Ruth Ladenstein, Jochen Rössler, Guy Makin, Dermot Murphy, Bruce Morland, Sucheta Vaidya, Estelle Thebaud, Natasha van Eijkelenburg, Deborah A Tweddle, Giuseppe Barone, Julie Tandonnet, Nadege Corradini, Pascal Chastagner, Catherine Paillard, Francisco J Bautista, Soledad Gallego Melcon, Bram De Wilde, Lynley Marshall, Juliet Gray, Susan A Burchill, Gudrun Schleiermacher, Louis Chesler, Andrew Peet, Martin O Leach, Kieran McHugh, Roisin Hayes, Neil Jerome, Hubert Caron, Jennifer Laidler, Nicola Fenwick, Grace Holt, Veronica Moroz, Pamela Kearns, Simon Gates, Andrew D J Pearson, Keith Wheatley; Innovative Therapies for Children with Cancer (ITCC) and European Association for Neuroblastoma Research (SIOPEN)

Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial

CHORAL team: Susan Burchill
Read More
Date published: September 15, 2022
Authors: Marcus J. Brookes, Elizabeth A. Roundhill, Lee Jeys, Michael Parry, Susan A. Burchill, Kenneth S. Rankin

Membrane-type 1 matrix metalloproteinase as predictor of survival and candidate therapeutic target in Ewing sarcoma

CHORAL team: Elizabeth Roundhill, Susan Burchill
Read More
Date published: January 18, 2023
Authors: Marcus J. Brookes, Elizabeth A. Roundhill, Lee Jeys, Michael Parry, Susan A. Burchill, Kenneth S. Rankin

Reply to: Comment on: Membrane-type 1 matrix metalloproteinase as predictor of survival and candidate therapeutic target in Ewing sarcoma

CHORAL team: Elizabeth Roundhill, Susan Burchill
Read More
Date published: February 11, 2023
Authors: Elizabeth Ann Roundhill, Pan Pantziarka, Danielle E. Liddle, Lucy A. Shaw, Ghadeer Albadrani and Susan Ann Burchill

Exploiting the Stemness and Chemoresistance Transcriptome of Ewing Sarcoma to Identify Candidate Therapeutic Targets and Drug-Repurposing Candidates

CHORAL team: Elizabeth Roundhill, Susan Burchill
Read More

CHORAL

X-twitter Linkedin

Join our mailing list for the latest news & updates

* indicates required

Intuit Mailchimp

By joining our mailing list, you agree to communications from CHORAL in accordance with the terms set out in our Privacy Policy.

© 2024 CHORAL. All rights reserved.

Website by Proportion Marketing